Leitlinie
Blood Pressure Targets in the 2025 AHA/ACC/Multisociety High Blood Pressure Guideline
JACC · 2025-11 · 86 (18) · 1529-1531
DOI: 10.1016/j.jacc.2025.09.002 ↗Kurz gefasst
Leitlinie in der Zeitschrift JACC, 2025-11. Verfasst von Ji-Guang Wang. Beteiligte Einrichtung: The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address: jigua…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
antihypertensive treatmentblood pressureguidelinehypertension
Autor:innen und Institutionen
- The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address: jiguangwang@rjh.com.cn.
Zitieren
APA
Wang, J. G. (2025). Blood Pressure Targets in the 2025 AHA/ACC/Multisociety High Blood Pressure Guideline. JACC, 86(18), 1529-1531. https://doi.org/10.1016/j.jacc.2025.09.002
Vancouver
Wang JG. Blood Pressure Targets in the 2025 AHA/ACC/Multisociety High Blood Pressure Guideline. JACC. 2025;86(18):1529-1531. doi:10.1016/j.jacc.2025.09.002
BibTeX
@article{Wang2025,
author = {Wang, Ji-Guang},
title = {Blood Pressure Targets in the 2025 AHA/ACC/Multisociety High Blood Pressure Guideline},
journal = {JACC},
year = {2025},
volume = {86},
number = {18},
pages = {1529--1531},
doi = {10.1016/j.jacc.2025.09.002}
}
EUVIMED